This website is intended for journalists outside the US/UK/Canada, who are interested in media information from Boehringer Ingelheim.

Top Stories

 

  •   

    EC approval for Boehringer Ingelheim’s oncology treatment

  •  

    IPF Tweet Chat

    Events and Initiatives

    IPF Tweet Chat

    24 February 2015


    Education Hub

     

     

    INFOGRAPHIC

    Nintedanib* Lume-Lung
    1 Clinical Trial

    INFOGRAPHIC

    Afatinib* Lux-Lung 3 & 6
    Clinical Trials

    Tweets from @Boehringer